about
International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease statesNeuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinaseCardiovascular effects of hormone therapy for prostate cancerThiorphan, tiopronin, and related analogs as substrates and inhibitors of peptidylglycine alpha-amidating monooxygenase (PAM)Neuropeptides bombesin and calcitonin inhibit apoptosis-related elemental changes in prostate carcinoma cell lines.Antagonist of growth hormone-releasing hormone induces apoptosis in LNCaP human prostate cancer cells through a Ca2+-dependent pathway.A history of prostate cancer treatmentTargeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels.Luteinising hormone releasing hormone analogues in the treatment of prostate cancer.Challenges in design and characterization of ligand-targeted drug delivery systems.Cancer treatment using peptides: current therapies and future prospectsIssues related to targeted delivery of proteins and peptides.Leuprolide acetate: a drug of diverse clinical applications.Activin receptor signaling regulates prostatic epithelial cell adhesion and viability.Substituted hippurates and hippurate analogs as substrates and inhibitors of peptidylglycine alpha-hydroxylating monooxygenase (PHM).New agonist- and antagonist-based treatment approaches for advanced prostate cancer.Neuroendocrine differentiation of prostate cancer: a review.Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs.Discovery of LHRH and development of LHRH analogs for prostate cancer treatment.Nanoparticulate delivery of LHRH analogue for the treatment of prostate cancer.A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analoguesAlteration of gonadotropin-releasing hormone receptor expression with the progression of prostate cancer in the Dunning rat adenocarcinoma sublines.Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238.Antagonists of growth hormone-releasing hormone inhibit proliferation induced by inflammation in prostatic epithelial cells.Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers.Recent Innovations in Peptide Based Targeted Drug Delivery to Cancer Cells.
P2860
Q24643524-208E3100-D6E2-42A8-9A6C-C4657AE12F44Q24746249-1CC6F428-31E5-4800-8CFA-00156A18B0C9Q26801112-AB90D953-9132-471C-8870-2C7404FD83F1Q28572374-331D5B44-B17F-43FD-B24C-5B1932D7C51EQ31043038-BF127DCF-4E02-49C8-A62F-7226E6F1BFB9Q33927273-F54AD157-2F58-41CA-A741-B0336B8D7CEBQ34013878-FD326EB1-5050-4533-B339-72644234008BQ34101055-8DCEF6BD-7F22-4451-8F8C-B6E77992A272Q35020521-4FAF3375-4A37-4062-82DC-0D09FC6A8229Q36346851-7B4DF7E9-D5F2-4628-BEBE-E1BC824A1E37Q36515785-A2F2D306-7C4C-4A92-8599-BA9A2E1528E6Q36616311-2730E37A-34E6-42CC-8FA5-63EC08CFC069Q36985884-CE9FB6BE-B944-410D-8ACB-8E4E044A4CBAQ37133929-FF6107C5-BB3F-4187-89D3-46A72995D1A5Q37157310-9D3B1175-37C5-436B-A4E9-D6FA2902F337Q38042768-66B1EB16-9D36-41EC-97B5-10FB0F4BF31AQ38326554-E13824AE-3713-47B8-BF88-CF671307321FQ38364462-6CBD78C1-3D23-4927-BB2B-BAF3FB1D3F40Q39267156-5E657849-6D75-4106-A3E0-017354165F9EQ39387700-6EFA4376-EE08-4990-8E06-3987F3DD9959Q39735399-7175A5C9-B11B-4C91-B6F7-593D1F0BCF28Q40389907-10835649-62B5-446A-A858-F579C74B787EQ40778582-3F6A8970-90F4-4C01-BA57-C8547889DDDCQ42321749-0D85F234-B082-4778-A6DD-CB1A1A1E5748Q44059662-27D002E9-7A75-402F-9AC0-EB7AE6CB0205Q47825566-1BA9995A-9BD2-4256-AEE1-7F7B5237C964Q50865530-BACB2E30-B9BC-477A-86F8-D3DE839BAF67
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
name
Peptide analogs in the therapy of prostate cancer.
@ast
Peptide analogs in the therapy of prostate cancer.
@en
Peptide analogs in the therapy of prostate cancer.
@nl
type
label
Peptide analogs in the therapy of prostate cancer.
@ast
Peptide analogs in the therapy of prostate cancer.
@en
Peptide analogs in the therapy of prostate cancer.
@nl
prefLabel
Peptide analogs in the therapy of prostate cancer.
@ast
Peptide analogs in the therapy of prostate cancer.
@en
Peptide analogs in the therapy of prostate cancer.
@nl
P2093
P2860
P1433
P1476
Peptide analogs in the therapy of prostate cancer
@en
P2093
A M Comaru-Schally
A Plonowski
P2860
P304
P356
10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K
P577
2000-10-01T00:00:00Z